Auto-Analysis for Ki-67 Indices of Breast Cancer Using Specified Computer Software and a Virtual Microscopy

• Kazuya Kuraoka

  Department of Diagnostic Pathology, National Hospital Organization, Kure Medical Center/Chugoku Cancer Center, Kure, Japan

• Kiyomi Taniyama

  Department of Diagnostic Pathology, National Hospital Organization, Kure Medical Center/Chugoku Cancer Center, Kure, Japan, Institute for Clinical Research, National Hospital Organization, Kure Medical Center/Chugoku Cancer Center, Kure, Japan

• Miho Tanaka

  Department of Diagnostic Pathology, National Hospital Organization, Kure Medical Center/Chugoku Cancer Center, Kure, Japan

• Yukari Nakagawa

  Department of Diagnostic Pathology, National Hospital Organization, Kure Medical Center/Chugoku Cancer Center, Kure, Japan

• Naoko Yasumura

  Department of Diagnostic Pathology, National Hospital Organization, Kure Medical Center/Chugoku Cancer Center, Kure, Japan

• Tamaki Toda

  Department of Diagnostic Pathology, National Hospital Organization, Kure Medical Center/Chugoku Cancer Center, Kure, Japan, Institute for Clinical Research, National Hospital Organization, Kure Medical Center/Chugoku Cancer Center, Kure, Japan

• Mikie Shitaune

  Department of Diagnostic Pathology, National Hospital Organization, Kure Medical Center/Chugoku Cancer Center, Kure, Japan

• Akihisa Saito

  Department of Diagnostic Pathology, National Hospital Organization, Kure Medical Center/Chugoku Cancer Center, Kure, Japan

• Junichi Sakane

  Department of Diagnostic Pathology, National Hospital Organization, Kure Medical Center/Chugoku Cancer Center, Kure, Japan

• Yoko Kodama

  Department of Diagnostic Pathology, National Hospital Organization, Kure Medical Center/Chugoku Cancer Center, Kure, Japan

• Toshinao Nishimura

  Department of Diagnostic Pathology, National Hospital Organization, Kure Medical Center/Chugoku Cancer Center, Kure, Japan

• Nao Morii

  Department of Breast surgery, National Hospital Organization, Kure Medical Center/Chugoku Cancer Center, Kure, Japan

• Hirotoshi Takahashi

  Department of Breast surgery, National Hospital Organization, Kure Medical Center/Chugoku Cancer Center, Kure, Japan

• Hiroyasu Yamashiro

  Department of Breast surgery, National Hospital Organization, Kure Medical Center/Chugoku Cancer Center, Kure, Japan

 Ki-67 index is one of important markers that is correlated with chemotherapy response and prognosis of breast cancer patients. However, Ki-67 index is not easily provided and are limited by intra-observer error and potentially subjective decision making. We performed this study to develop an objective auto-analysis system to count Ki-67 indices. A total of185 invasive breast cancer cases were used. Immunohistochemical staining was performed using auto-stainer and MIB-1 antibody. The results were stored digitally by virtual microscopy and auto-analyzed by Genie/Aperio software (Vista, CA, USA). As for Ki-67 indices, a good correlation was observed between direct ocular observations and auto-analysis techniques (r = 0.94, p < 0.001). The index examined by auto-analysis was significantly correlated with nuclear atypia, mitotic counts, and nuclear grade of pT1 breast cancers. Auto-analysis of 5 high power fields was better correlated with nuclear grade than that of whole fields. Further, the Ki-67 index was better correlated with mitotic counts than with nuclear atypia.Auto-analysis can provide results concordant with those obtained by direct ocular observation in a short time. Auto-analysis is more likely to result in an objective observation and provide a means by which to standardize methods for immunohistochemical Ki-67 indices of breast cancer.

Lloyd MC, Allam-Nandyala P, Purohit CN, Burke N, Coppola D, Bui MM. Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: How reliable is it? J Pathol Inform 2010; 1: 29. http://dx.doi.org/10.4103/2153-3539.74186

Tanaka M, Kuraoka K, Taniyama K, et al. [Auto-analysis of immunohistochemical findings for breast cancer using specified software and virtual microscopy]. [Article in Japanese with English abstract]. Rinsho Byori 2012; 60: 206-11.

Domagala W, Markiewski M, Harezga B, Dukowicz A, Osborn M. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. Clin Cancer Res 1996; 2: 147-54.

Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 2004; 40: 205-11. http://dx.doi.org/10.1016/S0959-8049(03)00675-0

Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-50. http://dx.doi.org/10.1093/jnci/djp082

Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-47. http://dx.doi.org/10.1093/annonc/mdr304

Taniyama K, Ishida K, Toda T, et al. Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas. Breast Cancer 2008; 15: 231-40. http://dx.doi.org/10.1007/s12282-007-0026-8

The Japanese Breast Cancer Society, eds. General Rules for Clinical and Pathological Recording of Breast Cancer, 17th ed. Kanehara-shuppan 2012.

Mohammed ZM, Orange C, McMillan DC, et al. Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer 2012; 106: 383-8. http://dx.doi.org/10.1038/bjc.2011.569

• PDF